TY - JOUR
T1 - Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes
T2 - Diminishing toxic effects in intestinal epithelial cells
AU - Stenman, S. M.
AU - Lindfors, K.
AU - Venäläinen, J. I.
AU - Hautala, A.
AU - Männistö, P. T.
AU - Garcia-Horsman, J. A.
AU - Kaukovirta-Norja, Anu
AU - Auriola, S.
AU - Mauriala, T.
AU - Mäki, M.
AU - Kaukinen, J.
PY - 2010
Y1 - 2010
N2 - Currently the only treatment for coeliac disease is a lifelong gluten‐free diet excluding food products containing wheat, rye and barley. There is, however, only scarce evidence as to harmful effects of rye in coeliac disease. To confirm the assumption that rye should be excluded from the coeliac patient's diet, we now sought to establish whether rye secalin activates toxic reactions in vitro in intestinal epithelial cell models as extensively as wheat gliadin. Further, we investigated the efficacy of germinating cereal enzymes from oat, wheat and barley to hydrolyse secalin into short fragments and whether secalin‐induced harmful effects can be reduced by such pretreatment. In the current study, secalin elicited toxic reactions in intestinal Caco‐2 epithelial cells similarly to gliadin: it induced epithelial cell layer permeability, tight junctional protein occludin and ZO‐1 distortion and actin reorganization. In high‐performance liquid chromatography and mass spectroscopy (HPLC‐MS), germinating barley enzymes provided the most efficient degradation of secalin and gliadin peptides and was thus selected for further in vitro analysis. After germinating barley enzyme pretreatment, all toxic reactions induced by secalin were ameliorated. We conclude that germinating enzymes from barley are particularly efficient in the degradation of rye secalin. In future, these enzymes might be utilized as a novel medical treatment for coeliac disease or in food processing in order to develop high‐quality coeliac‐safe food products.
AB - Currently the only treatment for coeliac disease is a lifelong gluten‐free diet excluding food products containing wheat, rye and barley. There is, however, only scarce evidence as to harmful effects of rye in coeliac disease. To confirm the assumption that rye should be excluded from the coeliac patient's diet, we now sought to establish whether rye secalin activates toxic reactions in vitro in intestinal epithelial cell models as extensively as wheat gliadin. Further, we investigated the efficacy of germinating cereal enzymes from oat, wheat and barley to hydrolyse secalin into short fragments and whether secalin‐induced harmful effects can be reduced by such pretreatment. In the current study, secalin elicited toxic reactions in intestinal Caco‐2 epithelial cells similarly to gliadin: it induced epithelial cell layer permeability, tight junctional protein occludin and ZO‐1 distortion and actin reorganization. In high‐performance liquid chromatography and mass spectroscopy (HPLC‐MS), germinating barley enzymes provided the most efficient degradation of secalin and gliadin peptides and was thus selected for further in vitro analysis. After germinating barley enzyme pretreatment, all toxic reactions induced by secalin were ameliorated. We conclude that germinating enzymes from barley are particularly efficient in the degradation of rye secalin. In future, these enzymes might be utilized as a novel medical treatment for coeliac disease or in food processing in order to develop high‐quality coeliac‐safe food products.
KW - Caco-2
KW - coeliac disease
KW - germinating cereal enzymes
KW - innate immunity
KW - permeability
U2 - 10.1111/j.1365-2249.2010.04119.x
DO - 10.1111/j.1365-2249.2010.04119.x
M3 - Article
SN - 0009-9104
VL - 161
SP - 242
EP - 249
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
IS - 2
ER -